Hofseth BioCare Q3 2026 operating loss narrows 81% year-on-year to NOK 5.7 million

PUBT · 2d ago
Hofseth BioCare Q3 2026 operating loss narrows 81% year-on-year to NOK 5.7 million
  • Hofseth BioCare’s third-quarter 2026 EBITDA turned positive at NOK 4.4 million, versus negative NOK 21.1 million a year earlier.
  • Total operating revenues climbed 52% year-over-year to a quarterly record of NOK 83.5 million.
  • Quarter-end cash and cash equivalents totaled NOK 33.6 million, while total liquidity including available credit facilities reached NOK 42.5 million.
  • Midsund processed 3,349 tonnes of raw material, down 37% year-over-year, with no unplanned production stops.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hofseth BioCare ASA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060215OMX_____CNEWS_EN_GNW1001302120_en) on November 06, 2026, and is solely responsible for the information contained therein.